

Insights to Drug Access for Patients

This educational workshop is supported by Novartis.

Date: 7th September 2018

Time: 12:30 pm to 5pm

Venue: Academia L1-S2, SGH Campus
20 College Road, Singapore 169856

Objectives:

- 1) Describe the various access schemes used globally to ensure treatment access for patients
- 2) To comprehend how drug pricing policy will affect access including treatment options for the patients within the context of respective healthcare system
- 3) To discuss feasible implementation plan for participating countries to have sustainable access methods for the patients

Time	Topic	Speaker
12.30 pm to 1 pm	Registration	
1.00 pm to 1.10 pm	Opening Remarks	A/Prof. Lita Chew Sui Tjien Chief Pharmacist, Ministry of Health Singapore Assoc Prof, Department of Pharmacy, National University of Singapore Head of Pharmacy, National Cancer Centre Singapore
1.10 pm to 2.10 pm	Group Discussion 1: How would a government's drug pricing policy affect access? Case in study: Conventional Health Technology Assessment (HTA) vs. Multi-Criteria Decision Analysis (MCDA)	Prof. Maarten Postma University of Groningen, Netherlands
2.10 pm to 3.10 pm	Group Discussion 2: Based on #1, In order to bring access to the patients, what kind of methods under Managed Entry Agreement (MEA) will be suitable for your country? Case in study: Financial based real life examples vs. Performance based real life examples	
3.10 pm to 3.20 pm	Coffee break	
3.20 pm to 4.30 pm	Group Discussion 3: Based on #2, is the implementation of these methods feasible?	Prof. Maarten Postma University of Groningen, Netherlands
4.30 pm to 4.50 pm	Wrap up	
4.50 pm to 5.00 pm	Closing Remarks	A/Prof. Lita Chew Sui Tjien

** All the case in study would start off with a 15 min lecture, followed by small group discussions (30 min) and presentation by representative of each group and summary by speaker (15 to 25 mins)*

For Group Discussion

- 1: Lecture will address cost-effectiveness and MCDA methodologies. Examples will be taken from NICE and ZiN (Zorginstituut Nederland; care Institute NL)
- 2: Lecture will provide a brief introduction on MEAs and some examples (conditional reimbursement, financial arrangements etc...)
3. Examples on applications of MEAs in oncology and orphan drugs. Will break out into various groups
(a) single payer countries, (b) mixed payers (self-pay + reimbursed) and (c) self-pay countries